OSTN and myocardial infarction: The inhibition of Npr3 by osteocrin (either by exogenous administration, or in osteocrin-transgenic mice) results in a significantly increased survival of mice undergoing myocardial infarction induced chronic HF, accompanied by improved cardiac function, lesser degree of cardiac inflammatory processes, and smaller ischemic area [16].